Thanks @Quitman for that post.
With Relyvrio out of the way. Basically leaves ourselves v Riluzole and Radicava. Riluzole increases median survival by up to 19 months .
Radicava costs $145 K PY . Short half live. 6 months median survival . Folks, that is our opposition now. PAA are now in a unique situation of saying to BP this is what we want in $. That's my read.
Kpax
Thanks @Quitman for that post.With Relyvrio out of the way....
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $78.76M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.0¢ | 16.0¢ | $54.17K | 328.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 98500 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 15359 | 3 |
View Market Depth
| Last trade - 13.18pm 15/07/2025 (20 minute delay) ? |
| NUZ (ASX) Chart |